#CHECKMATE 577 FULL#
#CHECKMATE 577 TRIAL#
#CHECKMATE 577 PLUS#

#CHECKMATE 577 PLUS#

Patients in the Opdivo plus Yervoy arm received Opdivo 1 mg/kg plus Yervoy 3 mg/kg every three weeks for four cycles followed by Opdivo 240 mg every two weeks. Patients in the Opdivo plus chemotherapy arm received Opdivo 360 mg plus capecitabine and oxaliplatin (CapeOX) every three weeks or Opdivo 240 mg plus 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) every two weeks.

#CHECKMATE 577 TRIAL#

The company remains blinded to data from this arm and the trial continues in follow-up to allow the data to mature.Ĭheckmate -649 is a Phase 3 randomized, multi-center, open-label study evaluating Opdivo plus chemotherapy or the Opdivo plus Yervoy combination compared to chemotherapy alone in patients with previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma.

#CHECKMATE 577 FULL#

The company will complete a full evaluation of the available CheckMate -649 data and work with investigators to share the results at an upcoming medical conference, as well as discuss them with health authorities.ĬheckMate -649 is also evaluating the Opdivo plus Yervoy (ipilimumab) combination compared to chemotherapy in patients with gastric cancer, GEJ cancer or esophageal adenocarcinoma.

“We look forward to engaging health authorities worldwide with the goal of bringing this immunotherapy-based treatment option to patients as soon as possible.” Waxman, M.D., development lead, Gastrointestinal Cancers, Bristol Myers Squibb. “The results from CheckMate -649, the largest study of gastric and esophageal cancers conducted to date, indicate the potential for Opdivo plus chemotherapy to change practice in the first-line setting and become a new standard of care for certain patients with gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma,” said Ian M. “Immunotherapy helped transform how we care for our patients across different tumor types, and the encouraging results from CheckMate -649 represent a new opportunity to improve survival for patients beyond standard chemotherapy.” Janjigian, M.D., Principal Investigator, Chief, Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center. Responses to the current standard chemotherapy in patients are short lived, and less than 6% of patients with metastatic disease survive beyond five years,” said Yelena Y. “There is an urgent need to improve therapeutic options for patients with esophageal and stomach cancer. The safety profiles of Opdivo and chemotherapy in this trial are reflective of the known safety profiles of Opdivo and chemotherapy in first-line gastric and esophageal cancers. Opdivo is the first and only PD-1 inhibitor to demonstrate superior OS and PFS in combination with chemotherapy when compared to chemotherapy alone in patients with gastric cancer, GEJ cancer or esophageal adenocarcinoma. The OS benefit was also observed in the all-randomized population. PRINCETON, NJ, USA I AugI Bristol Myers Squibb (NYSE: BMY) today announced that CheckMate -649, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) plus chemotherapy compared to chemotherapy alone as a first-line treatment for metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma, met both primary endpoints of overall survival (OS) at a pre-specified interim analysis and progression-free survival (PFS) at final analysis in patients whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5.

Survival benefit observed in the primary population of patients whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5 and also in the all-randomized population Opdivo is the first and only PD-1 inhibitor to demonstrate superior overall survival and progression-free survival in combination with chemotherapy when compared to chemotherapy alone in patients with gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma

Checkmate 577